Low endotoxin gelatin market seen reaching $2.54 billion by 2030

The low endotoxin gelatin market is projected to grow from $1.84 billion in 2025 to $2.54 billion by 2030, driven by regenerative medicine, biopharmaceutical production and drug delivery demand. North America led the market in 2025, while Asia-Pacific is expected to post the fastest growth.

Why it matters: - Low endotoxin gelatin is used in drug delivery, tissue engineering and regenerative medicine, where purity and biocompatibility can affect safety and therapeutic performance. - Growth in this market tracks broader demand for high-purity materials in biomedical applications and advanced therapies. - Rising use of injectable gelatin products and biotech-grade formulations points to deeper adoption across pharmaceutical and life sciences workflows.

What happened: - The Business Research Company published a market study projecting the low endotoxin gelatin market will grow from $1.84 billion in 2025 to $1.96 billion in 2026. - The report forecasts the market will reach $2.54 billion by 2030. - The study estimates a 6.5% compound annual growth rate from 2025 to 2026 and a 6.7% CAGR through 2030. - North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period.

The details: - Low endotoxin gelatin is a specially purified gelatin with very low endotoxin levels designed to reduce the risk of unwanted immune responses. - The material is intended for sensitive biological settings, including drug delivery, tissue engineering and regenerative medicine. - The market’s recent growth has been supported by pharmaceutical research activity, tissue engineering projects, biotech laboratory expansion and early adoption of innovative drug delivery systems. - Growth expectations also reflect rising investments in biopharmaceutical production and development of new biotech-grade gelatin formulations. - The report highlights a shift toward sustainable manufacturing processes, biocompatible materials, broader regenerative medicine use and more advanced formulation methods. - The source release cites ASGCT and Citeline data showing 247 gene therapy candidates in Phase II trials at the end of Q1 2023, rising to 260 by the end of Q2 2023. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - A free sample of the report is available. - The full market report is also available.

Between the lines: - The forecast suggests low endotoxin gelatin is benefiting from a larger shift toward cell therapies, regenerative medicine and safer biomaterials. - The emphasis on purity and endotoxin safety indicates the market is closely tied to stricter requirements in research and clinical development. - Asia-Pacific’s growth outlook suggests manufacturing, biotech investment and therapeutic development are becoming more geographically distributed.

What's next: - Demand is expected to rise as regenerative medicine and biopharmaceutical production expand. - Continued growth in injectable gelatin products and cell culture applications could support further market gains through 2030. - The market’s trajectory will likely depend on how quickly biotech and pharmaceutical users adopt higher-purity gelatin inputs.